Building-Organizations-That-Keep-Pace-With-Change

This panel discussion from the Danaher Summit 2026 features CEO John Cox of Dine Therapeutics and Dr. Ann Lee of Prime Medicine exploring how biotech organizations must evolve to keep pace with rapid scientific and therapeutic change. The conversation covers organizational design principles for fast decision-making, the challenge of scaling operations as pipelines mature from early to late stage, and concrete case studies from gene therapy manufacturing. A major highlight is Prime Medicine's 'PPQ-as-you-go' innovation — pioneered with CDMO Aldevron — to align manufacturing process validation with breakthrough clinical timelines in an ultra-rare disease setting.

Key Takeaways

John Cox reduced committee structures at Dine Therapeutics to just two and argues that fast decision-making is a teachable skill requiring clear ownership at the right organizational level — not RACI diagrams or more committees.
Ann Lee's three-principle single-decision-maker model: the decision owner must be explicitly named, all parties must proactively share relevant information, and the rationale for the final decision must be communicated to everyone affected.
Prime Medicine cleared an IND in 2024 for a CD34 prime edited cell therapy approximately five years after prime editing's first publication, achieved breakthrough clinical data in two patients, and then pivoted the pipeline to manage investor runway.
Prime Medicine and Aldevron pioneered 'PPQ-as-you-go': making the first mRNA manufacturing lot under prospective PPQ conditions within a 2.5-3 month window by explicitly designating in protocols which validation activities could be deferred, keeping CMC hip-to-hip with clinical data.
The FDA mandates prospective process performance qualification for mRNA and guide RNA components in gene therapy even when classified as critical reagents rather than drug substance; a new FDA draft guidance on gene therapy and gene editing was released approximately June 10, 2026.
John Cox describes supply chain investment in biotech as requiring 'seeing around corners' two years ahead, and argues that operations leaders must resist finance pressure based solely on commercial forecasts when committing to cannonball-scale manufacturing bets.
Danaher Corporation's transformation from a multi-industry conglomerate to a pure-play life sciences company over 15 years required significant organizational investment because the existing structure was not built for that pace of change.
At Genentech, Ann Lee challenged an investment in 8 × 25,000-liter bioreactors at Vacaville by driving titer improvements from below 1 g/L to significantly above 1 g/L, ultimately making the facility's capacity unnecessary; it was written off and sold.